Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor
prognosis, despite surgical resection combined with radio-and chemotherapy. The major …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …

Gene fusions represent an important class of somatic alterations in cancer. We
systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in∼ 8%
of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single …

Gliomas are the most common and challenging malignancies of the central nervous system
(CNS), due to their infiltrative nature, tendency to recurrence, and poor response to …

Glioma represents a fast proliferating and highly invasive brain tumor which is resistant to
current therapies and invariably recurs. Despite some advancements in anti-glioma …

Chromosomal translocations that generate in-frame oncogenic gene fusions are notable
examples of the success of targeted cancer therapies,,. We have previously described gene …

Pediatric neoplasms in the central nervous system (CNS) are the leading cause of cancer-
related deaths in children. Recent developments in molecular analyses have greatly …